BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Maisey NR, Norman AR, Hill A, Massey A, Oates J, Cunningham D. CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials. Br J Cancer. 2005;93:740-743. [PMID: 16175188 DOI: 10.1038/sj.bjc.6602760] [Cited by in Crossref: 99] [Cited by in F6Publishing: 94] [Article Influence: 5.8] [Reference Citation Analysis]
Number Citing Articles
1 Ali CW, Kaye TF, Adamson DJ, Tait IS, Polignano FM, Highley MS. CA 19-9 and survival in advanced and unresectable pancreatic adenocarcinoma and cholangiocarcinoma. J Gastrointest Cancer. 2007;38:108-114. [PMID: 19089662 DOI: 10.1007/s12029-008-9019-x] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 0.8] [Reference Citation Analysis]
2 Kato T, Hashimoto Y, Okada S, Tozawa K, Takahashi S, Kohri K. Carbohydrate antigen 19-9-positive prostatic ductal adenocarcinoma effectively treated with cisplatin and gemcitabine. Int J Urol 2007;14:1103-6. [PMID: 18036053 DOI: 10.1111/j.1442-2042.2007.01908.x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
3 Hammad N, Heilbrun LK, Philip PA, Shields AF, Zalupski MM, Venkatramanamoorthy R, El-Rayes BF. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy. Asia Pac J Clin Oncol. 2010;6:98-105. [PMID: 20565421 DOI: 10.1111/j.1743-7563.2010.01290.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.9] [Reference Citation Analysis]
4 Wasan HS, Springett GM, Chodkiewicz C, Wong R, Maurel J, Barone C, Rosbrook B, Ricart AD, Kim S, Spano JP. CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone. Br J Cancer 2009;101:1162-7. [PMID: 19724276 DOI: 10.1038/sj.bjc.6605243] [Cited by in Crossref: 28] [Cited by in F6Publishing: 30] [Article Influence: 2.2] [Reference Citation Analysis]
5 Rieser CJ, Zenati M, Hamad A, Al Abbas AI, Bahary N, Zureikat AH, Zeh HJ 3rd, Hogg ME. CA19-9 on Postoperative Surveillance in Pancreatic Ductal Adenocarcinoma: Predicting Recurrence and Changing Prognosis over Time. Ann Surg Oncol. 2018;25:3483-3491. [PMID: 29786131 DOI: 10.1245/s10434-018-6521-7] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
6 Altwegg R, Ychou M, Guillaumon V, Thezenas S, Senesse P, Flori N, Mazard T, Caillo L, Faure S, Samalin E, Assenat E. Second-line therapy for gemcitabine-pretreated advanced or metastatic pancreatic cancer. World J Gastroenterol 2012; 18(12): 1357-1364 [PMID: 22493549 DOI: 10.3748/wjg.v18.i12.1357] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
7 Ballehaninna UK, Chamberlain RS. Serum CA 19-9 as a Biomarker for Pancreatic Cancer-A Comprehensive Review. Indian J Surg Oncol. 2011;2:88-100. [PMID: 22693400 DOI: 10.1007/s13193-011-0042-1] [Cited by in Crossref: 122] [Cited by in F6Publishing: 107] [Article Influence: 11.1] [Reference Citation Analysis]
8 Dumitra S, Jamal MH, Aboukhalil J, Doi SA, Chaudhury P, Hassanain M, Metrakos PP, Barkun JS. Pancreatic cancer and predictors of survival: comparing the CA 19-9/bilirubin ratio with the McGill Brisbane Symptom Score. HPB (Oxford) 2013;15:1002-9. [PMID: 23521164 DOI: 10.1111/hpb.12085] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
9 Song JY, Chen MQ, Guo JH, Lian SF, Xu BH. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients. Medicine (Baltimore). 2018;97:e9707. [PMID: 29369199 DOI: 10.1097/md.0000000000009707] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
10 Laurent L, Sefrioui D, Bignon AL, Parzy A, Sidali S, Hassine M, Gangloff A, Galais MP, Bouhier-Leporrier K, Michel P, Di Fiore F. CA19.9 decrease >15% is a predictor of favourable outcome in patients treated for advanced pancreatic carcinoma: analysis of two independent cohorts. HPB (Oxford) 2019;21:582-8. [PMID: 30466797 DOI: 10.1016/j.hpb.2018.09.006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
11 Lu C, Wonsidler JL, Li J, Du Y, Block T, Haab B, Chen S. Chemically-blocked antibody microarray for multiplexed high-throughput profiling of specific protein glycosylation in complex samples. J Vis Exp 2012;:e3791. [PMID: 22588202 DOI: 10.3791/3791] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
12 Takahashi H, Ohigashi H, Ishikawa O, Eguchi H, Gotoh K, Yamada T, Nakaizumi A, Uehara H, Tomita Y, Nishiyama K, Yano M. Serum CA19-9 alterations during preoperative gemcitabine-based chemoradiation therapy for resectable invasive ductal carcinoma of the pancreas as an indicator for therapeutic selection and survival. Ann Surg 2010;251:461-9. [PMID: 20134315 DOI: 10.1097/SLA.0b013e3181cc90a3] [Cited by in Crossref: 51] [Cited by in F6Publishing: 19] [Article Influence: 4.3] [Reference Citation Analysis]
13 Tsutsumi K, Kawamoto H, Hirao K, Sakakihara I, Yamamoto N, Noma Y, Fujii M, Kato H, Ogawa T, Ishida E. Monitoring of CA19-9 and SPan-1 can facilitate the earlier confirmation of progressing pancreatic cancer during chemotherapy. Pancreatology. 2012;12:409-416. [PMID: 23127528 DOI: 10.1016/j.pan.2012.07.009] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.4] [Reference Citation Analysis]
14 Nakai Y, Isayama H, Sasaki T, Takahara N, Hamada T, Uchino R, Mizuno S, Miyabayashi K, Yamamoto K, Mohri D. A retrospective analysis of early CA19-9 change in salvage chemotherapy for refractory pancreatic cancer. Cancer Chemother Pharmacol. 2013;72:1291-1297. [PMID: 24121456 DOI: 10.1007/s00280-013-2313-8] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.3] [Reference Citation Analysis]
15 Reitz D, Gerger A, Seidel J, Kornprat P, Samonigg H, Stotz M, Szkandera J, Pichler M. Combination of tumour markers CEA and CA19-9 improves the prognostic prediction in patients with pancreatic cancer. J Clin Pathol. 2015;68:427-433. [PMID: 25759406 DOI: 10.1136/jclinpath-2014-202451] [Cited by in Crossref: 26] [Cited by in F6Publishing: 25] [Article Influence: 3.7] [Reference Citation Analysis]
16 Aldakkak M, Christians KK, Krepline AN, George B, Ritch PS, Erickson BA, Johnston FM, Evans DB, Tsai S. Pre-treatment carbohydrate antigen 19-9 does not predict the response to neoadjuvant therapy in patients with localized pancreatic cancer. HPB (Oxford) 2015;17:942-52. [PMID: 26255895 DOI: 10.1111/hpb.12448] [Cited by in Crossref: 35] [Cited by in F6Publishing: 24] [Article Influence: 5.0] [Reference Citation Analysis]
17 Hochster HS, Haller DG, de Gramont A, Berlin JD, Philip PA, Moore MJ, Ajani JA. Consensus report of the International Society of Gastrointestinal Oncology on therapeutic progress in advanced pancreatic cancer. Cancer 2006;107:676-85. [DOI: 10.1002/cncr.22036] [Cited by in Crossref: 55] [Cited by in F6Publishing: 47] [Article Influence: 3.4] [Reference Citation Analysis]
18 Bauer TM, El-Rayes BF, Li X, Hammad N, Philip PA, Shields AF, Zalupski MM, Bekaii-Saab T. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials. Cancer. 2013;119:285-292. [PMID: 22786786 DOI: 10.1002/cncr.27734] [Cited by in Crossref: 70] [Cited by in F6Publishing: 70] [Article Influence: 7.0] [Reference Citation Analysis]
19 Hsu CP, Lee LY, Hsu JT, Hsu YP, Wu YT, Wang SY, Yeh CN, Chen TC, Hwang TL. CD44 Predicts Early Recurrence in Pancreatic Cancer Patients Undergoing Radical Surgery. In Vivo 2018;32:1533-40. [PMID: 30348713 DOI: 10.21873/invivo.11411] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
20 Sato Y, Fujimoto D, Uehara K, Shimizu R, Ito J, Kogo M, Teraoka S, Kato R, Nagata K, Nakagawa A, Otsuka K, Hamakawa H, Takahashi Y, Imai Y, Tomii K. The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma. BMC Cancer 2016;16. [DOI: 10.1186/s12885-016-2897-6] [Reference Citation Analysis]
21 Winter JM, Yeo CJ, Brody JR. Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer. J Surg Oncol. 2013;107:15-22. [PMID: 22729569 DOI: 10.1002/jso.23192] [Cited by in Crossref: 137] [Cited by in F6Publishing: 141] [Article Influence: 13.7] [Reference Citation Analysis]
22 Kasenda B, Bass A, Koeberle D, Pestalozzi B, Borner M, Herrmann R, Jost L, Lohri A, Hess V. Survival in overweight patients with advanced pancreatic carcinoma: a multicentre cohort study. BMC Cancer. 2014;14:728. [PMID: 25266049 DOI: 10.1186/1471-2407-14-728] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 3.3] [Reference Citation Analysis]
23 Sato Y, Fujimoto D, Uehara K, Shimizu R, Ito J, Kogo M, Teraoka S, Kato R, Nagata K, Nakagawa A, Otsuka K, Hamakawa H, Takahashi Y, Imai Y, Tomii K. The prognostic value of serum CA 19-9 for patients with advanced lung adenocarcinoma. BMC Cancer. 2016;16:890. [PMID: 27842505 DOI: 10.1186/s12885-016-2897-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
24 Mann BF, Goetz JA, House MG, Schmidt CM, Novotny MV. Glycomic and proteomic profiling of pancreatic cyst fluids identifies hyperfucosylated lactosamines on the N-linked glycans of overexpressed glycoproteins. Mol Cell Proteomics. 2012;11:M111.015792. [PMID: 22393262 DOI: 10.1074/mcp.m111.015792] [Cited by in Crossref: 33] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
25 Kobayashi S, Ueno M, Irie K, Goda Y, Aoyama T, Morinaga S, Ohkawa S, Morimoto M. Potential prognostic significance of a new proteomic profile in patients with advanced pancreatic adenocarcinoma. Pancreatology 2015;15:525-30. [PMID: 26255025 DOI: 10.1016/j.pan.2015.07.003] [Reference Citation Analysis]
26 Eskander MF, Bliss LA, Tseng JF. Pancreatic adenocarcinoma. Current Problems in Surgery 2016;53:107-54. [DOI: 10.1067/j.cpsurg.2016.01.001] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
27 Mizrahi JD, Surana R, Valle JW, Shroff RT. Pancreatic cancer. The Lancet 2020;395:2008-20. [DOI: 10.1016/s0140-6736(20)30974-0] [Cited by in Crossref: 153] [Cited by in F6Publishing: 118] [Article Influence: 76.5] [Reference Citation Analysis]
28 Xu B, Zheng WY, Jin DY, Ding WX, Lou WH, Ramsohok L. Predictive value of serum carbohydrate antigen 19-9 in malignant intraductal papillary mucinous neoplasms. World J Surg. 2011;35:1103-1109. [PMID: 21416173 DOI: 10.1007/s00268-011-1003-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
29 Spry N, Harvey J, Macleod C, Borg M, Ngan SY, Millar JL, Graham P, Zissiadis Y, Kneebone A, Carroll S, Davies T, Reece WH, Iacopetta B, Goldstein D. 3D radiotherapy can be safely combined with sandwich systemic gemcitabine chemotherapy in the management of pancreatic cancer: factors influencing outcome. Int J Radiat Oncol Biol Phys 2008;70:1438-46. [PMID: 18164859 DOI: 10.1016/j.ijrobp.2007.08.070] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 0.7] [Reference Citation Analysis]
30 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.issn.2078-6891.2011.021] [Cited by in F6Publishing: 220] [Reference Citation Analysis]
31 Yildirim BA, Özdemir Y, Colakoglu T, Topkan E. Impact of presence and degree of pretreatment weight loss in locally-advanced pancreatic cancer patients treated with definitive concurrent chemoradiotherapy. Pancreatology 2016;16:599-604. [DOI: 10.1016/j.pan.2016.03.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.5] [Reference Citation Analysis]
32 Wong D, Ko AH, Hwang J, Venook AP, Bergsland EK, Tempero MA. Serum CA19-9 decline compared to radiographic response as a surrogate for clinical outcomes in patients with metastatic pancreatic cancer receiving chemotherapy. Pancreas. 2008;37:269-274. [PMID: 18815548 DOI: 10.1097/mpa.0b013e31816d8185] [Cited by in Crossref: 62] [Cited by in F6Publishing: 26] [Article Influence: 4.4] [Reference Citation Analysis]
33 An X, Ding PR, Li YH, Wang FH, Shi YX, Wang ZQ, He YJ, Xu RH, Jiang WQ. Elevated neutrophil to lymphocyte ratio predicts survival in advanced pancreatic cancer. Biomarkers. 2010;15:516-522. [PMID: 20602543 DOI: 10.3109/1354750x.2010.491557] [Cited by in Crossref: 140] [Cited by in F6Publishing: 93] [Article Influence: 11.7] [Reference Citation Analysis]
34 Stieber P, Molina R, Gion M, Gressner A, Troalen F, Holdenrieder S, Auge JM, Zancan M, Wycislo M, Jarrige V. Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation of the analytical and clinical performance of the Access GI Monitor assay on the UniCel Dxl 800 Immunoassay System. Clin Chem Lab Med 2008;46:600-11. [PMID: 18598202 DOI: 10.1515/CCLM.2008.126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Ueno M, Li CP, Ikeda M, Ishii H, Mizuno N, Yamaguchi T, Ioka T, Oh DY, Ichikawa W, Okusaka T, Matsuyama Y, Arai D, Chen LT, Park YS, Furuse J. A randomized phase II study of gemcitabine plus Z-360, a CCK2 receptor-selective antagonist, in patients with metastatic pancreatic cancer as compared with gemcitabine plus placebo. Cancer Chemother Pharmacol 2017;80:307-15. [PMID: 28634650 DOI: 10.1007/s00280-017-3351-4] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
36 Molina V, Visa L, Conill C, Navarro S, Escudero JM, Auge JM, Filella X, Lopez-Boado MA, Ferrer J, Fernandez-Cruz L, Molina R. CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer. Tumour Biol. 2012;33:799-807. [PMID: 22203495 DOI: 10.1007/s13277-011-0297-8] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
37 Mahipal A, Tella SH, Kommalapati A, Goyal G, Soares H, Neuger A, Copolla D, Kim J, Kim R. Phase 1 trial of enzalutamide in combination with gemcitabine and nab-paclitaxel for the treatment of advanced pancreatic cancer. Invest New Drugs 2019;37:473-81. [PMID: 30298303 DOI: 10.1007/s10637-018-0676-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
38 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.1002/ijc.20037] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
39 Lévy P. Adénocarcinome du pancréas : le dosage du CA 19-9 a-t-il un intérêt ? La Presse Médicale 2008;37:88-94. [DOI: 10.1016/j.lpm.2007.05.029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Toledano-Fonseca M, Cano MT, Inga E, Rodríguez-Alonso R, Gómez-España MA, Guil-Luna S, Mena-Osuna R, de la Haba-Rodríguez JR, Rodríguez-Ariza A, Aranda E. Circulating Cell-Free DNA-Based Liquid Biopsy Markers for the Non-Invasive Prognosis and Monitoring of Metastatic Pancreatic Cancer. Cancers (Basel) 2020;12:E1754. [PMID: 32630266 DOI: 10.3390/cancers12071754] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
41 Chen Y, Shao Z, Chen W, Xie H, Wu Z, Qin G, Zhao N. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer. Oncotarget 2017;8:29925-34. [PMID: 28404893 DOI: 10.18632/oncotarget.15557] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
42 Smigielski JA, Piskorz L, Wawrzycki M, Dobielski P, Pikala M, Jabłoński S, Brocki M. Application of biochemical markers CA 19-9, CEA and C-reactive protein in diagnosis of malicious and benign pancreatic tumors. Arch Med Sci 2013;9:677-83. [PMID: 24049528 DOI: 10.5114/aoms.2013.36899] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
43 Ballehaninna UK, Chamberlain RS. The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. J Gastrointest Oncol. 2012;3:105-119. [PMID: 22811878 DOI: 10.3978/j.ssn.2078-6891.2011.021] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
44 Usón Junior PL, França MS, Rodrigues HV, Macedo AL, Goldenberg A, Smaletz O, Armentano DP, Simon SD, Gansl RC. Higher overall survival in metastatic pancreatic cancer: the impact of where and how treatment is delivered. Einstein (Sao Paulo) 2015;13:347-51. [PMID: 26313433 DOI: 10.1590/S1679-45082015AO3303] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.7] [Reference Citation Analysis]
45 Katz MH, Varadhachary GR, Fleming JB, Wolff RA, Lee JE, Pisters PW, Vauthey JN, Abdalla EK, Sun CC, Wang H. Serum CA 19-9 as a marker of resectability and survival in patients with potentially resectable pancreatic cancer treated with neoadjuvant chemoradiation. Ann Surg Oncol. 2010;17:1794-1801. [PMID: 20162463 DOI: 10.1245/s10434-010-0943-1] [Cited by in Crossref: 98] [Cited by in F6Publishing: 96] [Article Influence: 8.2] [Reference Citation Analysis]
46 Park JK, Paik WH, Ryu JK, Kim YT, Kim YJ, Kim J, Song BJ, Park JM, Yoon YB. Clinical significance and revisiting the meaning of CA 19-9 blood level before and after the treatment of pancreatic ductal adenocarcinoma: analysis of 1,446 patients from the pancreatic cancer cohort in a single institution. PLoS One. 2013;8:e78977. [PMID: 24250822 DOI: 10.1371/journal.pone.0078977] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 2.8] [Reference Citation Analysis]
47 Yang A, Zylberberg HM, Rustgi SD, Amin SP, Bar-Mashiah A, Boffetta P, Lucas AL. Beta-blockers have no impact on survival in pancreatic ductal adenocarcinoma prior to cancer diagnosis. Sci Rep 2021;11:1038. [PMID: 33441781 DOI: 10.1038/s41598-020-79999-0] [Reference Citation Analysis]
48 Wang M, Shi SB, Qi JL, Tang XY, Tian J. S-1 plus CIK as second-line treatment for advanced pancreatic cancer. Med Oncol 2013;30:747. [PMID: 24122257 DOI: 10.1007/s12032-013-0747-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.3] [Reference Citation Analysis]
49 Nakachi K, Furuse J, Ishii H, Suzuki E, Yoshino M. Prognostic factors in patients with gemcitabine-refractory pancreatic cancer. Jpn J Clin Oncol 2007;37:114-20. [PMID: 17272317 DOI: 10.1093/jjco/hyl144] [Cited by in Crossref: 43] [Cited by in F6Publishing: 41] [Article Influence: 2.9] [Reference Citation Analysis]
50 Zeeshan MS, Ramzan Z. Current controversies and advances in the management of pancreatic adenocarcinoma. World J Gastrointest Oncol 2021; 13(6): 472-494 [PMID: 34163568 DOI: 10.4251/wjgo.v13.i6.472] [Reference Citation Analysis]
51 Al-Shamsi HO, Alzahrani M, Wolff RA. The clinical utility of normal range carbohydrate antigen 19-9 level as a surrogate marker in evaluating response to treatment in pancreatic cancer-a report of two cases. J Gastrointest Oncol 2016;7:E45-51. [PMID: 27284488 DOI: 10.21037/jgo.2016.01.05] [Cited by in Crossref: 20] [Cited by in F6Publishing: 8] [Article Influence: 3.3] [Reference Citation Analysis]
52 Kang J, Hwang I, Yoo C, Kim KP, Jeong JH, Chang HM, Lee SS, Park DH, Song TJ, Seo DW, Lee SK, Kim MH, Hong SM, Shin SH, Hwang DW, Song KB, Lee JH, Kim SC, Ryoo BY. Nab-paclitaxel plus gemcitabine versus FOLFIRINOX as the first-line chemotherapy for patients with metastatic pancreatic cancer: retrospective analysis. Invest New Drugs. 2018;36:732-741. [PMID: 29616439 DOI: 10.1007/s10637-018-0598-5] [Cited by in Crossref: 58] [Cited by in F6Publishing: 59] [Article Influence: 14.5] [Reference Citation Analysis]
53 Colloca G, Venturino A, Guarneri D. CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience. Med Oncol 2016;33:103. [PMID: 27522503 DOI: 10.1007/s12032-016-0817-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
54 Mitsunaga S, Kinoshita T, Hasebe T, Nakagohri T, Konishi M, Takahashi S, Gotohda N, Ochiai A. Low Serum Level of Cholinesterase at Recurrence of Pancreatic Cancer Is a Poor Prognostic Factor and Relates to Systemic Disorder and Nerve Plexus Invasion. Pancreas 2008;36:241-8. [DOI: 10.1097/mpa.0b013e31815b6b2b] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
55 Okano K, Suto H, Oshima M, Ando Y, Nagao M, Kamada H, Kobara H, Masaki T, Okuyama H, Okita Y, Tsuji A, Suzuki Y. 18F-fluorodeoxyglucose positron emission tomography to indicate conversion surgery in patients with initially unresectable locally advanced pancreatic cancer. Jpn J Clin Oncol 2018;48:434-41. [PMID: 29590448 DOI: 10.1093/jjco/hyy033] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
56 Farina A, Dumonceau JM, Frossard JL, Hadengue A, Hochstrasser DF, Lescuyer P. Proteomic analysis of human bile from malignant biliary stenosis induced by pancreatic cancer. J Proteome Res. 2009;8:159-169. [PMID: 19055478 DOI: 10.1021/pr8004925] [Cited by in Crossref: 43] [Cited by in F6Publishing: 44] [Article Influence: 3.3] [Reference Citation Analysis]
57 Koom WS, Seong J, Kim YB, Pyun HO, Song SY. CA 19-9 as a predictor for response and survival in advanced pancreatic cancer patients treated with chemoradiotherapy. Int J Radiat Oncol Biol Phys. 2009;73:1148-1154. [PMID: 18760544 DOI: 10.1016/j.ijrobp.2008.06.1483] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 2.1] [Reference Citation Analysis]
58 Yu S, Zhang C, Xie KP. Therapeutic resistance of pancreatic cancer: Roadmap to its reversal. Biochim Biophys Acta Rev Cancer 2021;1875:188461. [PMID: 33157162 DOI: 10.1016/j.bbcan.2020.188461] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
59 Grossberg AJ, Chu LC, Deig CR, Fishman EK, Hwang WL, Maitra A, Marks DL, Mehta A, Nabavizadeh N, Simeone DM, Weekes CD, Thomas CR Jr. Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma. CA Cancer J Clin 2020;70:375-403. [PMID: 32683683 DOI: 10.3322/caac.21626] [Cited by in Crossref: 25] [Cited by in F6Publishing: 28] [Article Influence: 12.5] [Reference Citation Analysis]
60 Balzano G, Di Carlo V. Is CA 19-9 useful in the management of pancreatic cancer? The Lancet Oncology 2008;9:89-91. [DOI: 10.1016/s1470-2045(08)70011-1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
61 Akisik MF, Sandrasegaran K, Bu G, Lin C, Hutchins GD, Chiorean EG. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Radiology. 2010;256:441-449. [PMID: 20515976 DOI: 10.1148/radiol.10091733] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 6.4] [Reference Citation Analysis]
62 Vaklavas C, Tsimberidou AM, Wen S, Hong D, Wheler J, Ng CS, Naing A, Uehara C, Wolff RA, Kurzrock R. Phase 1 clinical trials in 83 patients with pancreatic cancer: The M. D. Anderson Cancer Center experience. Cancer 2011;117:77-85. [PMID: 20737567 DOI: 10.1002/cncr.25346] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
63 Chung KH, Ryu JK, Lee BS, Jang DK, Lee SH, Kim YT. Early decrement of serum carbohydrate antigen 19-9 predicts favorable outcome in advanced pancreatic cancer. J Gastroenterol Hepatol 2016;31:506-12. [PMID: 26250642 DOI: 10.1111/jgh.13075] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
64 Hotakainen K, Tanner P, Alfthan H, Haglund C, Stenman U. Comparison of three immunoassays for CA 19-9. Clinica Chimica Acta 2009;400:123-7. [DOI: 10.1016/j.cca.2008.10.033] [Cited by in Crossref: 16] [Cited by in F6Publishing: 12] [Article Influence: 1.2] [Reference Citation Analysis]
65 Quan Q, Wang Y, Wang F, Zhang D, Chen X, He W, Zhang B, Guo G. Real World First-Line Treatments and Outcomes of Nab-Paclitaxel Plus Gemcitabine, mFOLFIRINOX and GEMOX in Unresectable Pancreatic Cancer from a Chinese Single Institution. Curr Oncol 2020;28:209-19. [PMID: 33704188 DOI: 10.3390/curroncol28010023] [Reference Citation Analysis]
66 Bernhard J, Dietrich D, Glimelius B, Hess V, Bodoky G, Scheithauer W, Herrmann R. Estimating prognosis and palliation based on tumour marker CA 19-9 and quality of life indicators in patients with advanced pancreatic cancer receiving chemotherapy. Br J Cancer 2010;103:1318-24. [PMID: 20877359 DOI: 10.1038/sj.bjc.6605929] [Cited by in Crossref: 29] [Cited by in F6Publishing: 24] [Article Influence: 2.4] [Reference Citation Analysis]
67 Scarà S, Bottoni P, Scatena R. CA 19-9: Biochemical and Clinical Aspects. Adv Exp Med Biol 2015;867:247-60. [PMID: 26530370 DOI: 10.1007/978-94-017-7215-0_15] [Cited by in Crossref: 99] [Cited by in F6Publishing: 91] [Article Influence: 16.5] [Reference Citation Analysis]
68 Boeck S, Hinke A, Wilkowski R, Heinemann V. Importance of performance status for treatment outcome in advanced pancreatic cancer. World J Gastroenterol 2007; 13(2): 224-227 [PMID: 17226900 DOI: 10.3748/wjg.v13.i2.224] [Cited by in CrossRef: 46] [Cited by in F6Publishing: 42] [Article Influence: 3.1] [Reference Citation Analysis]
69 Hartwig W, Strobel O, Hinz U, Fritz S, Hackert T, Roth C, Büchler MW, Werner J. CA19-9 in potentially resectable pancreatic cancer: perspective to adjust surgical and perioperative therapy. Ann Surg Oncol. 2013;20:2188-2196. [PMID: 23247983 DOI: 10.1245/s10434-012-2809-1] [Cited by in Crossref: 146] [Cited by in F6Publishing: 133] [Article Influence: 14.6] [Reference Citation Analysis]
70 Vargas CVF, Ceolin L, Scheffel RS, Benini AF, Graudenz MS, Maia AL. The tissue expression pattern of CA 19.9 is associated with oncological features in medullary thyroid carcinoma. Endocrine. 2020;70:544-551. [PMID: 32535684 DOI: 10.1007/s12020-020-02377-3] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Boeck S, Stieber P, Holdenrieder S, Wilkowski R, Heinemann V. Prognostic and Therapeutic Significance of Carbohydrate Antigen 19-9 as Tumor Marker in Patients with Pancreatic Cancer. Oncology 2006;70:255-64. [DOI: 10.1159/000094888] [Cited by in Crossref: 100] [Cited by in F6Publishing: 102] [Article Influence: 6.3] [Reference Citation Analysis]
72 Fujino Y, Ueda T, Kamigaki T, Takase S, Ajiki T, Kamoda Y, Matsumoto I, Yasuda T, Kuroda Y. Impact of gemcitabine on the survival of patients with stage IV pancreatic cancer. Pancreas 2007;34:335-9. [PMID: 17414056 DOI: 10.1097/MPA.0b013e31802638] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
73 Reni M, Cereda S, Balzano G, Passoni P, Rognone A, Fugazza C, Mazza E, Zerbi A, Di Carlo V, Villa E. Carbohydrate antigen 19-9 change during chemotherapy for advanced pancreatic adenocarcinoma. Cancer 2009;115:2630-9. [DOI: 10.1002/cncr.24302] [Cited by in Crossref: 76] [Cited by in F6Publishing: 77] [Article Influence: 5.8] [Reference Citation Analysis]
74 Tingle SJ, Severs GR, Goodfellow M, Moir JA, White SA. NARCA: A novel prognostic scoring system using neutrophil-albumin ratio and Ca19-9 to predict overall survival in palliative pancreatic cancer. J Surg Oncol 2018;118:680-6. [PMID: 30196571 DOI: 10.1002/jso.25209] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 4.5] [Reference Citation Analysis]
75 Du R, Sun W, Lin L, Sun J, Peng K, Xu Y, Xu M, Chen Y, Bi Y, Wang W, Li D, Lu J. Serum CA 19-9 and risk of incident diabetes in middle-aged and elderly Chinese: a prospective cohort study. Acta Diabetol 2017;54:201-8. [DOI: 10.1007/s00592-016-0937-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
76 Chen S, Wang G, Niu X, Zhao J, Tan W, Wang H, Zhao L, Ge Y. Combination of AZD2281 (Olaparib) and GX15-070 (Obatoclax) results in synergistic antitumor activities in preclinical models of pancreatic cancer. Cancer Lett 2014;348:20-8. [PMID: 24534203 DOI: 10.1016/j.canlet.2014.02.010] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
77 Batra A, Tang PA, Cheung WY. Prognostic Significance of Disease Control at 12 Weeks in Patients With Advanced Pancreatic Cancer Receiving FOLFIRINOX as First-line Chemotherapy. Am J Clin Oncol 2021;44:519-25. [PMID: 34366400 DOI: 10.1097/COC.0000000000000856] [Reference Citation Analysis]
78 Boeck S, Schulz C, Stieber P, Holdenrieder S, Weckbach S, Heinemann V. Assessing prognosis in metastatic pancreatic cancer by the serum tumor marker CA 19-9: pretreatment levels or kinetics during chemotherapy? Onkologie 2007;30:39-42. [PMID: 17264524 DOI: 10.1159/000097764] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
79 Nguyen KT, Kalyan A, Beasley HS, Singhi AD, Sun W, Zeh HJ, Normolle D, Bahary N. Gemcitabine/nab-paclitaxel as second-line therapy following FOLFIRINOX in metastatic/advanced pancreatic cancer-retrospective analysis of response. J Gastrointest Oncol 2017;8:556-65. [PMID: 28736642 DOI: 10.21037/jgo.2017.01.23] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.8] [Reference Citation Analysis]
80 Davis VW, Schiller DE, Eurich D, Bathe OF, Sawyer MB. Pancreatic ductal adenocarcinoma is associated with a distinct urinary metabolomic signature. Ann Surg Oncol. 2013;20 Suppl 3:S415-S423. [PMID: 23096698 DOI: 10.1245/s10434-012-2686-7] [Cited by in Crossref: 35] [Cited by in F6Publishing: 28] [Article Influence: 3.5] [Reference Citation Analysis]
81 Kang YM, Wang H, Li R, Pan G. Prognostic Role of Carbohydrate Antigen 19 to 9 in Predicting Survival of Patients With Pancreatic Cancer: A Meta-Analysis. Technol Cancer Res Treat 2021;20:15330338211043030. [PMID: 34617852 DOI: 10.1177/15330338211043030] [Reference Citation Analysis]
82 Fong ZV, Winter JM. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive. Cancer J. 2012;18:530-538. [PMID: 23187839 DOI: 10.1097/ppo.0b013e31827654ea] [Cited by in Crossref: 71] [Cited by in F6Publishing: 44] [Article Influence: 7.9] [Reference Citation Analysis]
83 Han ES, Lee HH, Lee JS, Song KY, Park CH, Jeon HM. At which stage of gastric cancer progression do levels of carcinoembryonic antigen and carbohydrate antigen 19-9 increase? Application in advanced gastric cancer treatment. J Gastric Cancer 2014;14:123-8. [PMID: 25061540 DOI: 10.5230/jgc.2014.14.2.123] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
84 Sun KD, Zhang YJ, Zhu LP, Yang B, Wang SY, Yu ZH, Zhang HC, Chen X. Abnormal serum carbohydrate antigen 19-9 levels in a patient with splenic retiform haemangioendothelioma concomitant with hepatic amyloidosis: A case report. World J Clin Cases 2020; 8(6): 1108-1115 [PMID: 32258081 DOI: 10.12998/wjcc.v8.i6.1108] [Reference Citation Analysis]
85 Peixoto RD, Speers C, McGahan CE, Renouf DJ, Schaeffer DF, Kennecke HF. Prognostic factors and sites of metastasis in unresectable locally advanced pancreatic cancer. Cancer Med. 2015;4:1171-1177. [PMID: 25891650 DOI: 10.1002/cam4.459] [Cited by in Crossref: 45] [Cited by in F6Publishing: 43] [Article Influence: 6.4] [Reference Citation Analysis]
86 Motoi F, Rikiyama T, Katayose Y, Egawa S, Unno M. Retrospective Evaluation of the Influence of Postoperative Tumor Marker Status on Survival and Patterns of Recurrence After Surgery for Pancreatic Cancer Based on RECIST Guidelines. Ann Surg Oncol 2011;18:371-9. [DOI: 10.1245/s10434-010-1311-x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 2.3] [Reference Citation Analysis]
87 Maeda S, Motoi F, Onogawa T, Morikawa T, Shigeru O, Sakata N, Takadate T, Naitoh T, Rikiyama T, Katayose Y. Paclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective study. Int J Clin Oncol. 2011;16:539-545. [PMID: 21455624 DOI: 10.1007/s10147-011-0220-8] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
88 Mirkin KA, Hollenbeak CS, Wong J. Prognostic impact of carbohydrate antigen 19-9 level at diagnosis in resected stage I-III pancreatic adenocarcinoma: a U.S. population study. J Gastrointest Oncol 2017;8:778-88. [PMID: 29184681 DOI: 10.21037/jgo.2017.07.04] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
89 Von Hoff DD, Ramanathan RK, Borad MJ, Laheru DA, Smith LS, Wood TE, Korn RL, Desai N, Trieu V, Iglesias JL. Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. J Clin Oncol. 2011;29:4548-4554. [PMID: 21969517 DOI: 10.1200/jco.2011.36.5742] [Cited by in Crossref: 692] [Cited by in F6Publishing: 389] [Article Influence: 62.9] [Reference Citation Analysis]
90 Zhao JG, Hu Y, Liao Q, Niu ZY, Zhao YP. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer. World J Gastroenterol 2014; 20(19): 5875-5880 [PMID: 24914348 DOI: 10.3748/wjg.v20.i19.5875] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
91 Goldstein D, Van Hazel G, Walpole E, Underhill C, Kotasek D, Michael M, Shapiro J, Davies T, Reece W, Harvey J, Spry N. Gemcitabine with a specific conformal 3D 5FU radiochemotherapy technique is safe and effective in the definitive management of locally advanced pancreatic cancer. Br J Cancer 2007;97:464-71. [PMID: 17653074 DOI: 10.1038/sj.bjc.6603900] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 2.1] [Reference Citation Analysis]
92 Park BB, Park JO, Lee HR, Lee J, Choi DW, Choi SH, Heo JS, Lee JK, Lee KT, Lim DH, Park YS, Lim HY, Kang WK, Park K. A phase II trial of gemcitabine plus capecitabine for patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2007;60:489-94. [PMID: 17396266 DOI: 10.1007/s00280-006-0390-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
93 Lim KH, Kim TY, Lee KH, Han SW, Oh DY, Im SA, Kim TY, Bang YJ. Efficacy of infusional 5-fluorouracil, doxorubicin, and mitomycin-C (iFAM) in the treatment of patients with gemcitabine-pretreated pancreatic cancer and analysis of prognostic factors in a salvage setting. Cancer Chemother Pharmacol 2011;68:1017-26. [PMID: 21327930 DOI: 10.1007/s00280-011-1584-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
94 Chau I, Cunningham D, Russell C, Norman AR, Kurzawinski T, Harper P, Harrison P, Middleton G, Daniels F, Hickish T, Prendeville J, Ross PJ, Theis B, Hull R, Walker M, Shankley N, Kalindjian B, Murray G, Gillbanks A, Black J. Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials. Br J Cancer 2006;94:1107-15. [PMID: 16622436 DOI: 10.1038/sj.bjc.6603058] [Cited by in Crossref: 58] [Cited by in F6Publishing: 52] [Article Influence: 3.6] [Reference Citation Analysis]
95 Kato T, Ban D, Tateishi U, Ogura T, Ogawa K, Ono H, Mitsunori Y, Kudo A, Tanaka S, Tanabe M. Reticular pattern around superior mesenteric artery in computed tomography imaging predicting poor prognosis of pancreatic head cancer. J Hepatobiliary Pancreat Sci 2020;27:114-23. [PMID: 31702106 DOI: 10.1002/jhbp.700] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
96 Hernandez JM, Cowgill SM, Al-Saadi S, Collins A, Ross SB, Cooper J, Villadolid D, Zervos E, Rosemurgy A. CA 19-9 velocity predicts disease-free survival and overall survival after pancreatectomy of curative intent. J Gastrointest Surg. 2009;13:349-353. [PMID: 18972170 DOI: 10.1007/s11605-008-0696-3] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 2.5] [Reference Citation Analysis]
97 Humphris JL, Chang DK, Johns AL, Scarlett CJ, Pajic M, Jones MD, Colvin EK, Nagrial A, Chin VT, Chantrill LA, Samra JS, Gill AJ, Kench JG, Merrett ND, Das A, Musgrove EA, Sutherland RL, Biankin AV;  NSW Pancreatic Cancer Network. The prognostic and predictive value of serum CA19.9 in pancreatic cancer. Ann Oncol. 2012;23:1713-1722. [PMID: 22241899 DOI: 10.1093/annonc/mdr561] [Cited by in Crossref: 148] [Cited by in F6Publishing: 135] [Article Influence: 14.8] [Reference Citation Analysis]
98 Hess V, Glimelius B, Grawe P, Dietrich D, Bodoky G, Ruhstaller T, Bajetta E, Saletti P, Figer A, Scheithauer W. CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial. Lancet Oncol. 2008;9:132-138. [PMID: 18249033 DOI: 10.1016/s1470-2045(08)70001-9] [Cited by in Crossref: 154] [Cited by in F6Publishing: 75] [Article Influence: 11.0] [Reference Citation Analysis]